Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trial

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) inhibitors reduce cardiovascular events in high-risk patients. Whether the addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sposito, Andrei C., Breder, Ikaro, Barreto, Joaquim, Breder, Jessica, Bonilha, Isabella, Lima, Marcus, Oliveira, Alessandra, Wolf, Vaneza, Luchiari, Beatriz, do Carmo, Helison R., Munhoz, Daniel, Oliveira, Daniela, Coelho-Filho, Otavio R., Coelho, Otavio R., Matos-Souza, Jose Roberto, Moura, Filipe A., de Carvalho, Luiz Sergio F., Nadruz, Wilson, Quinaglia, Thiago, Kimura-Medorima, Sheila T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356512/
https://www.ncbi.nlm.nih.gov/pubmed/35933413
http://dx.doi.org/10.1186/s12933-022-01584-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356512/
https://www.ncbi.nlm.nih.gov/pubmed/35933413
http://dx.doi.org/10.1186/s12933-022-01584-8

Ejemplares similares